
Akero Therapeutics AKRO
Quarterly report 2025-Q3
added 11-07-2025
Akero Therapeutics Shares 2011-2026 | AKRO
Annual Shares Akero Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 67.1 M | 52.6 M | 39 M | 34.8 M | 34 M | 15.1 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 67.1 M | 15.1 M | 40.4 M |
Quarterly Shares Akero Therapeutics
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 82 M | 81.7 M | 72.4 M | 69.4 M | 69.2 M | 55.8 M | 55.6 M | 51.9 M | 46.9 M | 46.9 M | 38.7 M | - | 35 M | 34.9 M | 34.9 M | 34.8 M | 34.7 M | 34.7 M | 34 M | 28.6 M | 28.5 M | 28.6 M | 28 M | 3.27 M | 168 K | 239 K | 127 K | 92.2 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 82 M | 92.2 K | 38.2 M |
Shares of other stocks in the Biotechnology industry
| Issuer | Shares | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
33.4 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
16.8 M | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
115 M | - | 5.93 % | $ 314 M | ||
|
Albireo Pharma
ALBO
|
19.2 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
17.9 M | - | 10.36 % | $ 9.8 M | ||
|
I-Mab
IMAB
|
187 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
44.7 B | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
118 M | - | -13.47 % | $ 169 M | ||
|
Ascendis Pharma A/S
ASND
|
54.8 M | $ 215.54 | -1.16 % | $ 5 B | ||
|
Aptinyx
APTX
|
67.7 M | - | -39.0 % | $ 4.57 M | ||
|
Aquestive Therapeutics
AQST
|
107 M | $ 3.88 | -1.27 % | $ 415 M | ||
|
Midatech Pharma plc
MTP
|
80.5 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
46.7 M | $ 19.23 | - | $ 899 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
45 M | - | - | $ 26.5 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
13.3 M | $ 8.18 | -2.97 % | $ 109 M | ||
|
Ayala Pharmaceuticals
AYLA
|
15.4 M | - | - | $ 7.46 M | ||
|
AgeX Therapeutics
AGE
|
1.08 K | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
1.24 M | - | -24.86 % | $ 820 K | ||
|
Atreca
BCEL
|
38.6 M | - | -11.76 % | $ 5.79 M | ||
|
Acasti Pharma
ACST
|
12.1 M | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
1.42 B | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
110 M | - | - | $ 546 M | ||
|
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - | ||
|
Cara Therapeutics
CARA
|
54.1 M | - | -3.03 % | $ 260 M | ||
|
Adverum Biotechnologies
ADVM
|
19.8 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
15.8 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
6.02 M | - | -9.65 % | $ 45.9 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
11.5 M | $ 0.71 | 17.15 % | $ 8.13 M | ||
|
Avenue Therapeutics
ATXI
|
1.3 M | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
255 M | $ 1.32 | -5.71 % | $ 337 M | ||
|
CytomX Therapeutics
CTMX
|
138 M | $ 4.24 | -4.83 % | $ 585 M | ||
|
Cyclacel Pharmaceuticals
CYCC
|
22.3 M | - | -5.98 % | $ 34.1 M | ||
|
ChemoCentryx
CCXI
|
69.9 K | - | - | $ 3.74 B | ||
|
Genmab A/S
GMAB
|
630 M | $ 25.81 | 0.51 % | $ 16.6 B | ||
|
Aytu BioScience
AYTU
|
6.28 M | $ 2.65 | 0.76 % | $ 16.6 M | ||
|
Dynavax Technologies Corporation
DVAX
|
130 M | - | - | $ 2.02 B | ||
|
BioDelivery Sciences International
BDSI
|
99.3 M | - | -4.8 % | $ 255 M | ||
|
Enochian Biosciences
ENOB
|
165 M | - | - | $ 40.5 M | ||
|
Aeglea BioTherapeutics
AGLE
|
78.2 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
186 M | - | - | $ 867 M | ||
|
Eton Pharmaceuticals
ETON
|
26.9 M | $ 22.97 | -3.53 % | $ 618 M | ||
|
Exelixis
EXEL
|
272 M | $ 41.57 | 0.39 % | $ 11.3 B | ||
|
Bellerophon Therapeutics
BLPH
|
9.55 M | - | -74.18 % | $ 955 K | ||
|
Fortress Biotech
FBIO
|
20.8 M | $ 2.92 | -2.01 % | $ 60.7 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
192 M | $ 4.31 | -2.49 % | $ 826 M | ||
|
Homology Medicines
FIXX
|
12.3 M | - | 0.77 % | $ 53.4 M | ||
|
Akouos
AKUS
|
34.4 M | - | 0.23 % | $ 488 M |